Pharmabiz9h
Diadem presents new findings on early Alzheimer’s disease detection using p53-specific antibody at CTAD 2024
Diadem presents new findings on early Alzheimer’s disease detection using p53-specific antibody at CTAD 2024: Milano, Italy Tuesday, November 5, 2024, 18:00 Hrs [IST] Diadem SpA ...
Pharmabiz11h
Gland Pharma in Q2FY25 reports Rs. 1,405.8 crore revenue and profit dip by 16% at Rs.163.5 crore
Gland Pharma in Q2FY25 reports Rs. 1,405.8 crore revenue and profit dip by 16% at Rs.163.5 crore: Our Bureau, Bengaluru Tuesday, November 5, 2024, 16:15 Hrs [IST] Gland Pharma, a ...
Pharmabiz13h
Oak Hill Bio, Chiesi announce first European patient enrolled in phase 2b study of OHB-607 for prevention of BPD in premature infants
Oak Hill Bio, Chiesi announce first European patient enrolled in phase 2b study of OHB-607 for prevention of BPD in premature infants: Parma, Italy Tuesday, November 5, 2024, 14:0 ...
Pharmabiz9h
Health groups and patients calls for government interference to make rare disease drugs affordable
Health groups and patients calls for government interference to make rare disease drugs affordable: Our Bureau, New Delhi Tuesday, November 5, 2024, 18:10 Hrs [IST] Health groups ...
Pharmabiz17h
Novo Nordisk announces positive results from phase 3 ESSENCE trial of semaglutide 2.4 mg to treat adults with MASH and liver fibrosis
Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...
Pharmabiz15h
Venus Remedies’ Baddi robotic pre-filled syringe facility receives Malaysian PIC/S GMP approval
Venus Remedies’ Baddi robotic pre-filled syringe facility receives Malaysian PIC/S GMP approval: Our Bureau, Mumbai Tuesday, November 5, 2024, 12:15 Hrs [IST] Venus Remedies Lim ...
Pharmabiz5h
Healthcare payments company QubeHealth raises pre series A from Unicorn India Ventures and CanBank VC
Deep-tech focused, early-stage venture fund, Unicorn India Ventures and CanBank Venture Capital Fund, from VI Fund ‘Empower India Fund’ led an undisclosed investment into the Mumbai-based healthcare ...
Pharmabiz12h
Prokarium expands IP portfolio with two new US patents strengthening its position in bladder cancer
Prokarium expands IP portfolio with two new US patents strengthening its position in bladder cancer: London, UK Tuesday, November 5, 2024, 15:00 Hrs [IST] Prokarium, a biopharmace ...
Pharmabiz10h
Epredia’s SlideMate Laser slide printer receives innovative technology designation from Vizient
Epredia’s SlideMate Laser slide printer receives innovative technology designation from Vizient: Portsmouth, New Hampshire Tuesday, November 5, 2024, 17:00 Hrs [IST] Epredia, a ...
Pharmabiz11h
MannKind completes phase 1 trial of nintedanib DPI for pulmonary fibrotic diseases
MannKind completes phase 1 trial of nintedanib DPI for pulmonary fibrotic diseases: Danbury, Connecticut Tuesday, November 5, 2024, 16:00 Hrs [IST] MannKind Corporation, a company ...
Pharmabiz15h
ALX Oncology to present results from phase 1b/2 trial of evorpacept in combo with zanidatamab at SABCS 2024
ALX Oncology to present results from phase 1b/2 trial of evorpacept in combo with zanidatamab at SABCS 2024: South San Francisco, California Tuesday, November 5, 2024, 12:00 Hrs [ ...
Pharmabiz6h
Memo Therapeutics appoints Frits van Alphen, MD as chief development officer
Memo Therapeutics AG (MTx), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces that Frits van Alphen, MD has been ...